A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
about
Focus on adoptive T cell transfer trials in melanomaChimeric antigen receptor-modified T cells in chronic lymphoid leukemiaT cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemiaGenetic engineering of T cells for adoptive immunotherapyAdoptive cell transfer: a clinical path to effective cancer immunotherapyAdoptive T cell therapy for cancer in the clinicTargeting folate receptor alpha for cancer treatmentChimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsChimeric Antigen Receptors Modified T-Cells for Cancer TherapyTherapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapyA current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancerNanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and ImmunotherapyImmunotherapy of Childhood SarcomasAdoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptorsControl of CD8 T-Cell Infiltration into Tumors by Vasculature and MicroenvironmentCAR T Cell Therapy: A Game Changer in Cancer TreatmentB7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer lookCAR T cells for solid tumors: armed and ready to go?CARs in chronic lymphocytic leukemia -- ready to driveProgress and prospects for engineered T cell therapiesGenetically modified T cells for the treatment of malignant diseaseImmunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerNovel immunotherapies for hematologic malignanciesAdoptive T-cell therapy for LeukemiaClinical application of adoptive T cell therapy in solid tumorsCD19 as an attractive target for antibody-based therapyChimeric antigen receptor therapy for cancerTumor infiltrating lymphocytes in ovarian cancerAntigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T CellsGenetically modified T cells in cancer therapy: opportunities and challengesImmunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapiesAdvances in the treatment of metastatic melanoma: adoptive T-cell therapyPSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical modelsImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationToxicity and management in CAR T-cell therapyCAR therapy: the CD19 paradigmTargeted immune therapy of ovarian cancerAre BiTEs the "missing link" in cancer therapy?Smart CARs engineered for cancer immunotherapyCombining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma
P2860
Q21328679-D15ED2A9-C798-4989-B7CC-A04489DDA70CQ24594920-50435693-F361-47B0-B8A9-F01A84A0391DQ24632975-40AAE4E7-F718-4EEB-BCCC-C543DCD70C06Q24642718-1DCF0F1C-00A4-41B6-B9B7-52A280923CE7Q24644774-8224BD9A-A9A0-4FBB-9E52-99067CFBC5E3Q24680405-1A1AA550-33DD-4C20-BE6B-535867A4A949Q26744215-1DA4E8F4-F2D7-471E-B91E-529050976AE2Q26753082-21202710-CB7D-4003-82BA-ADFDB6D62996Q26773309-75C16215-59CD-4EF8-948B-9F8D08D52FBEQ26779938-33CA0107-8935-46C8-AACE-A3A38FCFB0E5Q26781856-7C228C1F-CCF0-46BD-BD13-AEF38C2700C7Q26782566-C8517998-478E-4587-AAE7-2554EA7DD42EQ26795369-C6CA9A0D-9668-4377-935B-0D6CC0D84C34Q26795540-8E12D554-79F9-4FEF-8D0B-463AAE0358FDQ26799117-8CFA71C7-5CFD-4D44-A0E6-083AAFA653E7Q26822769-33C84177-55E9-4B2F-A961-0FA41284DA2DQ26824446-3A224137-8E74-40D0-917F-6B59FC24AE04Q26825489-9FA710FC-410A-4AED-BD2A-3B106B15E4ADQ26830526-B27BBBDD-77D4-482E-84A6-11A9E13D5E77Q26852923-3713BE95-A3C6-4D43-ADC8-B1319F57C371Q26860657-7EC05094-D67F-4CF2-ADBD-0794888B78F9Q26996829-9A7550E2-E470-4895-8B03-189086AC25A2Q27004436-C89095D5-B7F0-4462-AFD1-6F5A572A5EF3Q27006934-F357E46D-9337-40A5-B80C-8EEBC8EB5CA3Q27011283-1AE8DEE9-9DB3-474B-890C-34A4F43012F6Q27011836-A994D357-9C11-4B86-976A-126D4AEA3768Q27013599-D3019179-AFBE-48AC-BB5F-EF644FBEE415Q27021878-7F55C2AE-2B07-4D3D-9CC8-CDDCDFFFFC97Q27026484-A8CED763-0027-488C-8791-3DF78D1FA2C8Q27026627-4A94648C-B8AF-471D-A984-983A7E93C1BCQ27027243-030A0CB4-565F-478D-834D-C8E8A8B9F315Q27027803-4A51AEFB-8FDB-4A9A-A77D-49D3CBA6FD0EQ27339832-23746B94-AFAB-474D-8CB1-BE840F91F545Q28068378-B0B48168-B170-4BBC-ABF4-F67D8A45F6CCQ28075314-3B50873F-5A98-4EB4-9135-CF5C3C5BA200Q28081642-D56D3F63-A365-41C9-8692-DB103E89B3F9Q28082828-DC6CE1BD-A89F-4CC2-9E10-DB584AA1A922Q28083907-8EBBC553-D643-4F19-A500-7FC7353BFD67Q28087236-1B4D451B-03E8-48E5-9112-A07711C9E12AQ28537688-3A30C0C9-1FA4-4FEE-B3E6-B079FAF454A0
P2860
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
@ast
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
@en
type
label
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
@ast
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
@en
prefLabel
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
@ast
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
@en
P2093
P2860
P1476
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
@en
P2093
Clara C Chen
Donald E White
James C Yang
Jennifer A Westwood
John R Wunderlich
Linda L Parker
Linda Rogers-Freezer
Michael H Kershaw
Patrick Hwu
P2860
P304
P356
10.1158/1078-0432.CCR-06-1183
P407
P433
P577
2006-10-01T00:00:00Z